Share Price, page-2603

Credit to @bilgewater on Sharetease Clinuvel forum for this link to the Marcus Today podcast with Henry Jennings talking to Jon Pilcher a few days ago.

https://www.buzzsprout.com/1852332/11621637

- Jon said going it alone for NNZ-2591 is still an option based on how strong the results from the Phase 2 trials are. He alluded to the possibility of developing the US market and farming out ROW to potential partners.

- Neuren has around $40 million cash in bank.

- He says Neuren is about to apply to the FDA for approval to begin Prader Willi phase 2 trial.

- Says negotiations are well advanced but won’t commit to a date for announcing a ROW partnership deal. He says could be this side of March 12th or after.

- The interviewer asked a very pertinent question (something I’ve been thinking about): what else does Neuren have in the pipeline down the track. Would the company sit back and be a cash generating holding company for Neuren IP or would it look for other growth opportunities? Jon intimated that there could be a third opportunity but didn’t elaborate on whether this a drug variation/new drug or other fields of medicine i.e. neurodegenerative disorders.